A
Alpine Immune Sciences Inc
F:34LA
Alpine Immune Sciences Inc
F:34LA
Price:
59
EUR
Market Closed
Market Cap:
€4B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
A
|
Alpine Immune Sciences Inc
F:34LA
|
US |
|
A
|
Ausom Enterprise Ltd
NSE:AUSOMENT
|
IN |
|
C
|
C&S Paper Co Ltd
SZSE:002511
|
CN |
|
S
|
Solvay SA
XBER:SOL
|
BE |
|
J
|
Jiangsu Pacific Quartz Co Ltd
SSE:603688
|
CN |
|
M
|
MediaZen Inc
KOSDAQ:279600
|
KR |
|
S
|
Seabridge Gold Inc
NYSE:SA
|
CA |
|
Orient Press Ltd
NSE:ORIENTLTD
|
IN |
|
Arezzo Industria e Comercio SA
BOVESPA:ARZZ3
|
BR |
Balance Sheet
Balance Sheet Decomposition
Alpine Immune Sciences Inc
Alpine Immune Sciences Inc
Balance Sheet Decomposition is not available for
Alpine Immune Sciences Inc
Alpine Immune Sciences Inc
Balance Sheet
Alpine Immune Sciences Inc
Alpine Immune Sciences Inc
Currency: USD
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
28
|
25
|
24
|
8
|
11
|
16
|
35
|
68
|
13
|
44
|
|
| Cash Equivalents |
28
|
25
|
24
|
8
|
11
|
16
|
35
|
68
|
13
|
44
|
|
| Short-Term Investments |
0
|
62
|
37
|
73
|
42
|
24
|
71
|
94
|
224
|
283
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
25
|
1
|
1
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
25
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Other Current Assets |
1
|
0
|
1
|
1
|
1
|
1
|
1
|
4
|
3
|
2
|
|
| Total Current Assets |
28
|
88
|
62
|
83
|
54
|
42
|
107
|
192
|
241
|
330
|
|
| PP&E Net |
0
|
0
|
0
|
1
|
1
|
12
|
11
|
11
|
10
|
9
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
1
|
12
|
11
|
11
|
10
|
9
|
|
| Accumulated Depreciation |
1
|
2
|
0
|
0
|
1
|
1
|
2
|
2
|
2
|
3
|
|
| Intangible Assets |
0
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
26
|
53
|
36
|
41
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Total Assets |
29
N/A
|
88
+208%
|
62
-30%
|
85
+38%
|
55
-36%
|
54
-1%
|
144
+166%
|
256
+78%
|
287
+12%
|
380
+32%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
1
|
1
|
2
|
0
|
2
|
2
|
1
|
3
|
4
|
4
|
|
| Accrued Liabilities |
2
|
3
|
5
|
0
|
4
|
5
|
6
|
10
|
15
|
22
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
1
|
2
|
0
|
3
|
5
|
3
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
1
|
32
|
52
|
36
|
16
|
|
| Total Current Liabilities |
2
|
4
|
7
|
2
|
8
|
9
|
41
|
70
|
58
|
42
|
|
| Long-Term Debt |
0
|
0
|
0
|
4
|
2
|
5
|
8
|
3
|
0
|
0
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
11
|
33
|
62
|
49
|
10
|
|
| Total Liabilities |
2
N/A
|
4
+83%
|
7
+48%
|
6
-3%
|
10
+63%
|
25
+139%
|
82
+233%
|
135
+65%
|
107
-21%
|
52
-52%
|
|
| Equity | |||||||||||
| Common Stock |
42
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
126
|
149
|
180
|
9
|
46
|
88
|
116
|
166
|
224
|
256
|
|
| Additional Paid In Capital |
110
|
232
|
236
|
88
|
91
|
117
|
178
|
287
|
405
|
584
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
| Total Equity |
26
N/A
|
84
+220%
|
55
-34%
|
79
+42%
|
45
-43%
|
30
-34%
|
62
+111%
|
121
+94%
|
179
+48%
|
328
+83%
|
|
| Total Liabilities & Equity |
29
N/A
|
88
+208%
|
62
-30%
|
85
+38%
|
55
-36%
|
54
-1%
|
144
+166%
|
256
+78%
|
287
+12%
|
380
+32%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
3
|
4
|
4
|
14
|
14
|
19
|
24
|
30
|
46
|
60
|
|
Switch to:
Switch to:
See Also
Discover More
